Genomic variations associated with risk and protection against vincristine-induced peripheral neuropathy in pediatric cancer patients.
Saved in:
| Title: | Genomic variations associated with risk and protection against vincristine-induced peripheral neuropathy in pediatric cancer patients. |
|---|---|
| Authors: | Mufti K; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada., Cordova M; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Scott EN; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Trueman JN; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, BC, Canada., Lovnicki JM; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, BC, Canada., Loucks CM; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.; Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Rassekh SR; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.; Division of Hematology, Oncology & Bone Marrow Transplant, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Ross CJD; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. colin.ross@ubc.ca.; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada. colin.ross@ubc.ca.; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. colin.ross@ubc.ca., Carleton BC; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. bcarleton@popi.ubc.ca.; British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada. bcarleton@popi.ubc.ca.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. bcarleton@popi.ubc.ca.; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, BC, Canada. bcarleton@popi.ubc.ca. |
| Corporate Authors: | Canadian Pharmacogenomics Network for Drug Safety Consortium |
| Source: | NPJ genomic medicine [NPJ Genom Med] 2024 Nov 05; Vol. 9 (1), pp. 56. Date of Electronic Publication: 2024 Nov 05. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature in partnership with the Center of Excellence in Genomic Medicine Research at King Abdulaziz University Country of Publication: England NLM ID: 101685193 Publication Model: Electronic Cited Medium: Internet ISSN: 2056-7944 (Electronic) Linking ISSN: 20567944 NLM ISO Abbreviation: NPJ Genom Med Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2056-7944 |
|---|---|
| DOI: | 10.1038/s41525-024-00443-7 |
